2020
Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
Severe B, Tetrault JM, Madden L, Heimer R. Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention. Drug And Alcohol Dependence 2020, 213: 108116. PMID: 32599493, DOI: 10.1016/j.drugalcdep.2020.108116.Peer-Reviewed Original ResearchOpioid treatment programsOpioid use disorderOpioid agonist treatmentHCV treatmentOUD treatmentTreatment retentionHepatitis C virus infection treatmentControl groupSurvival analysisHepatitis C virus infectionTreatment programHCV care continuumC virus infectionChronic HCV infectionOutcomes of interestHCV infectionAgonist treatmentPatient retentionCare continuumVirus infectionTreatment groupsUse disordersPatientsBaseline covariatesInfection treatment
2009
Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection
Paintsil E, Verevochkin SV, Dukhovlinova E, Niccolai L, Barbour R, White E, Toussova OV, Alexander L, Kozlov AP, Heimer R. Hepatitis C virus infection among drug injectors in St Petersburg, Russia: social and molecular epidemiology of an endemic infection. Addiction 2009, 104: 1881-1890. PMID: 19712125, PMCID: PMC2763027, DOI: 10.1111/j.1360-0443.2009.02687.x.Peer-Reviewed Original ResearchConceptsInjection drug usersHepatitis C virusRespondent-driven samplingPrevalent infectionMajority of IDUsHepatitis C virus infectionSustained virological responseC virus infectionRespondent-driven sampleAssociation of genotypesIDU communityVirological responseHCV infectionAntiviral therapyC virusGenotype 3aDrug injectionVirus infectionDrug injectorsBlood samplesHCV sequencesDrug usersEndemic infectionInfectionMolecular epidemiology